Dan is Executive Vice President of TGen, Director of TGen's Translational Drug Development Division and Head of TGen's Pancreatic Cancer Research Program. He is also Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona and served as director of the Arizona Cancer Center. He is also Chief Scientific Officer for U.S. Oncology. Dan's career is focused on the discovery and development of new anticancer agents. He has been deeply involved in the development of many agents, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. Dan's present focus is the development of molecularly targeted therapies, especially the discovery of new targets in pancreatic cancer and the discovery and development of drugs to treat this lethal disease. Dan's basic laboratory focus is in vitro drug sensitivity testing to individualize treatment for the patient, mechanisms of gene amplification, particularly of extrachromosomal DNA, and understanding of and targeting telomere maintenance mechanisms. Dan is past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is founder and board member of ILEX Oncology and founder and Editor Emeritus of Investigational New Drugs The Journal of New Anticancer Agents; Co-Editor of ONE, ONcology Economics; and, Editor of Molecular Cancer Therapeutics. Dan was appointed to President Bush's National Cancer Advisory Board in June 2004. He has published more than 515 papers, 127 book chapters, and more than 850 abstracts.